Compare ALDX & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALDX | CERS |
|---|---|---|
| Founded | 2004 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.0M | 276.0M |
| IPO Year | 2014 | 1997 |
| Metric | ALDX | CERS |
|---|---|---|
| Price | $5.54 | $2.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $9.50 | $4.00 |
| AVG Volume (30 Days) | 836.4K | ★ 1.6M |
| Earning Date | 02-27-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $199,191,000.00 |
| Revenue This Year | N/A | $25.31 |
| Revenue Next Year | $36.25 | $9.50 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.03 |
| 52 Week Low | $1.14 | $1.12 |
| 52 Week High | $7.20 | $2.96 |
| Indicator | ALDX | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 65.70 | 58.68 |
| Support Level | $5.05 | $2.44 |
| Resistance Level | $5.43 | $2.74 |
| Average True Range (ATR) | 0.31 | 0.16 |
| MACD | 0.14 | -0.00 |
| Stochastic Oscillator | 93.84 | 51.76 |
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.